CXCL8 and cancer: Past research leads to a conclusion that the old anti-Hansen’s disease sulfone antibiotic dapsone, when added to erlotinib, can be expected to mitigate all three IL-8-related erlotinib consequences that currently detract from erlotinib’s anti-cancer effectiveness.